Change in MAPSE During Treatment of Sepsis
Evaluation of Mitral Annulus Systolic Plane Excursion (MAPSE) in Emergency Department Patients With Sepsis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Alexis Salerno, MD
- Phone Number: (667) 214-2208
- Email: alexis.salerno@som.umaryland.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland Medical Center
-
Contact:
- Alexis Salerno, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of Sepsis or Septic Shock
Exclusion Criteria:
- Age equal to or less than 17
- patient in the emergency department
- Unable to perform POCUS exam due to medical necessity
- Patients without sepsis
- unable to obtain consent or have a legal representative consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with Sepsis
These are patients who present to the emergency department with sepsis.
They will have a MAPSE at the time of enrollment and then after initial treatment.
|
Patients will have standard care of sepsis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in MAPSE measurement
Time Frame: 1 hour after treatment initiation
|
Does the MAPSE change after treatment of MAPSE
|
1 hour after treatment initiation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ICU length of stay
Time Frame: until completion, anticipated 2 weeks.
|
In patients with a change in MAPSE measurement, do they have a difference in ICU length of stay.
|
until completion, anticipated 2 weeks.
|
|
Mortality Rate
Time Frame: until completion, anticipated 1 month.
|
In patients with a change in MAPSE measurement, do they have a different mortality rate?
|
until completion, anticipated 1 month.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HP-00102983
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.